



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,141	04/02/2007	Robert Brunham	APL-03-04-US	9254
<div>7590      01/11/2008</div> <div>Patrick J. Halloran, Ph.D. 3141 Muirfield Rd. Center Valley, PA 18034</div>				
EXAMINER				
OGUNBIYI, OLUWATOSIN A				
ART UNIT		PAPER NUMBER		
1645				
MAIL DATE		DELIVERY MODE		
01/11/2008		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/580,141	Applicant(s) BRUNHAM ET AL.	
	Examiner Oluwatosin Ogunbiyi	Art Unit 1645	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 02 April 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-38 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-38 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/ are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

**DETAILED ACTION**

Claims 1-38 are pending in the application.

***Election/Restrictions***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-15,20-22 and 30 drawn to an isolated and purified nucleic acid molecule comprising a nucleic acid sequence which encodes the polypeptide SEQ ID NO: 2 and its truncated form SEQ ID NO: 6 and an isolated and purified nucleic acid molecule comprising a nucleic acid sequence SEQ ID NO:1 and its truncated form SEQ ID NO: 5.

Group II, claim(s) 1-15,20-22 and 30 drawn to an isolated and purified nucleic acid molecule comprising a nucleic acid sequence which encodes the polypeptide SEQ ID NO: 4 and its truncated form SEQ ID NO: 8 and an isolated and purified nucleic acid molecule comprising a nucleic acid sequence SEQ ID NO: 3 and its truncated form SEQ ID NO: 7.

Group III, claim(s) 16-19 drawn to a method for preventing or treating Chlamydia infection comprising the step of administering an effective amount of a nucleic acid molecule which encodes the polypeptide SEQ ID NO: 2 and or its truncated form SEQ ID NO: 6.

Group IV, claim(s) 16-19 drawn to a method for preventing or treating Chlamydia infection comprising the step of administering an effective amount of a nucleic acid molecule which encodes the polypeptide SEQ ID NO: 4 and or its truncated form SEQ ID NO: 8.

Group V, claim(s) 23,26-29 and 31-37 drawn to the polypeptide with the amino acid sequence set forth in SEQ ID NO: 2 and its truncated form SEQ ID NO: 6 and a polypeptide encoded by the nuclei acid sequence set forth in SEQ ID NO: 1 and 5.

Group VI, claim(s) 23,26-29 and 31-37 drawn to the polypeptide with the amino acid sequence set forth in SEQ ID NO: 4 and its truncated form SEQ ID NO: 8 a polypeptide encoded by the nuclei acid sequence set forth in SEQ ID NO: 3 and 7.

Group VII, claim 25 drawn to an antibody against the polypeptide with the amino acid sequence set forth in SEQ ID NO: 2 and its truncated form SEQ ID NO: 6.

Group VIII, claim 25 drawn to an antibody against the polypeptide with the amino acid sequence set forth in SEQ ID NO: 4 and its truncated form SEQ ID NO: 8.

Group IX, claim 38 drawn to a method for preventing or treating Chlamydia infection comprising the step of administering an effective amount of the polypeptide with the amino acid sequence set forth in SEQ ID NO: 2 and or its truncated form SEQ ID NO: 6.

Group X, claim 38 drawn to a method for preventing or treating Chlamydia infection comprising the step of administering an effective amount of the polypeptide with the amino acid sequence set forth in SEQ ID NO: 4 and or its truncated form SEQ ID NO: 8.

Group XI, claim 24 drawn to a method for producing a polypeptide with the amino acid sequence set forth in SEQ ID NO: 2 and or its truncated form SEQ ID NO: 6.

Group XII, claim 24 drawn to a method for producing a polypeptide with the amino acid sequence set forth in SEQ ID NO: 4 and or its truncated form SEQ ID NO: 8.

The inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature of the first appearing invention is anticipated by the art Timms, P. WO 02/14516 A1. Timms et al teaches a nucleic acid molecule comprising a nucleic acid sequence which encodes SEQ ID NO:2. See attached sequence alignment for SEQ ID NO: 1 which encodes SEQ ID NO:2 (See p. 6 of the instant specification, Figure 1). Thus, group I, lacks unity with Groups II-XII, because the technical feature of Group I is anticipated by the art and therefore not "special" within the meaning of PCT Rule 13.2 because it does not provide for a contribution that the claimed invention makes over the art. Thus, the inventions listed in Groups I-XII lack unity of invention.

#### ***Notice of Possible Rejoinder***

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention

must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Oluwatosin Ogunbiyi whose telephone number is 571-272-9939. The examiner can normally be reached on M-F 8:30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Application/Control Number:  
10/580,141  
Art Unit: 1645

Page 7

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Oluwatosin Ogunbiyi  
Patent Examiner  
Art unit, 1645



SHANON FOLEY  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600